You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
綠葉製藥(02186.HK)新藥利斯的明多天貼劑獲英國上市批准
格隆匯 09-23 08:04

格隆匯9月23日丨綠葉製藥(02186.HK)發佈公吿,集團新藥利斯的明多日透皮貼劑(“利斯的明多天貼劑”或“LY30410”)已獲得英國藥品和保健品監管機構授予在英國的上市批准。利斯的明多天貼劑是集團開發的用於治療與阿爾茨海默病相關的輕中度痴呆症的給藥途徑創新藥。

集團的英國分公司是利斯的明多天貼劑在英國的上市許可持有人,並將負責該產品的銷售。此前,利斯的明多天貼劑已於2021年5月在多個歐盟國家獲得上市許可資格,並將由集團的合作伙伴Italfarmaco和Esteve進行商業化。利斯的明多天貼劑也預計將加速在全球許多其他發展中國家或新興市場上市。

根據披露,阿爾茨海默病仍然是全球範圍的一大健康難題,患者數量不斷增長。根據《2019年世界阿爾茨海默病報吿》,據估計,全球已有超過5,000萬名痴呆症患者,預計到2050年,這一數字將超過3倍至1.52億。超過50%的阿爾茲海默病患者的照護者稱其健康因照護責任而受到影響,每年全球的痴呆症治療費用估計約1萬億美元。

阿爾茨海默病新藥研發進展緩慢,現有治療藥物非常有限。利斯的明是目前治療阿爾茨海默病相關痴呆症的一線用藥,在全球市場銷售。隨着全球老齡化趨勢的推進,董事會相信,利斯的明多天貼劑未來會有良好的市場前景,並將豐富集團的未來產品組合。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account